Orlistat vs Mounjaro: two very different approaches to weight loss

How does each medicine work, and why does the mechanism matter?

Orlistat is a lipase inhibitor. It works entirely inside the gut, blocking enzymes that break down dietary fat so that roughly a third of the fat you eat passes through unabsorbed. It has no effect on appetite, no hormonal action and no impact on blood-sugar regulation. The practical upshot is that what you eat matters enormously: high-fat meals cause the unabsorbed fat to exit rapidly, producing well-documented side effects including oily stools and urgency. Most people find the medicine essentially acts as a dietary enforcer rather than a metabolic intervention. Mounjaro (tirzepatide) operates on a completely different level. It activates both GIP and GLP-1 receptors, two gut-hormone pathways involved in appetite signalling, blood-sugar control and gastric emptying. The result is a significant reduction in hunger and calorie intake that isn't dependent on willpower over individual meals. If you are weighing up newer injectable options more broadly, our page on Rybelsus and tirzepatide covers how Reta compares with Mounjaro as part of that wider picture. It is the only dual-agonist weight-loss medicine currently licensed in the UK. Understanding which mechanism suits a person's physiology and circumstances is precisely the kind of clinical judgement a prescriber makes during assessment, not something a comparison table can settle on its own.

What do the clinical trial results show for orlistat or Mounjaro?

The numbers diverge substantially. Orlistat trials typically show average weight reductions of around 5–7% over one year when combined with a reduced-calorie diet, though individual results vary widely. Mounjaro's SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks in adults without diabetes. In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide also produced greater average weight loss than semaglutide 2.4mg (Wegovy). The table below summarises the key factual differences.

The results gap between orlistat and Mounjaro is large enough that they are rarely genuine alternatives for the same patient) they tend to suit different starting points and different levels of clinical need.

Who might each option be right for, and what does eligibility actually look like?

Orlistat has been available far longer and is relatively familiar to GPs. It can be appropriate for people at an earlier stage of a weight-management journey, those who prefer an oral medicine with no injections, or those for whom the stronger options are contraindicated. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. NICE recommends tirzepatide for NHS use under stricter criteria (BMI ≥35 plus a qualifying comorbidity per TA1026), but private eligibility follows the licensed indication. A prescriber assesses the whole picture: current conditions, medicines, lifestyle, medical history and preferences. BMI alone is never the full story. If you're currently on orlistat and wondering whether Mounjaro might be a better fit, our page on switching from orlistat to Mounjaro covers exactly what that process involves. Equally, if you want a broader look at whether orlistat is better than Mounjaro for your specific situation, that page goes deeper on the practical trade-offs.

Is cost the right way to choose between them?

Orlistat is significantly cheaper. Lower-strength versions are available over the counter; prescription-strength orlistat costs a fraction of what Mounjaro typically does on the private market. That price gap is real and worth acknowledging. The question is what you're comparing. A medicine that costs less but produces a fraction of the average weight loss isn't necessarily the better value, it depends entirely on your goals, your health, and what a clinician advises. Mounjaro's private price has risen since Eli Lilly adjusted UK list pricing in September 2025, with typical private costs now ranging roughly £149–£375 per month depending on dose and provider, as widely reported. At nume, one transparent price covers the consultation, prescription, treatment and aftercare, details are on the treatment page. We're not trying to be the cheapest option; we're trying to be the most thorough one. If cost is your primary concern, our page on Mounjaro costs in the UK breaks down what drives the price and what to watch for. For context on how Mounjaro compares with other newer agents, the Mysimba vs Mounjaro page covers another oral medicine in this space. Which option suits you best is a clinical decision our prescribers make with you, not one a page like this can make for you. Speak to our prescribers through a free consultation and get a same-day clinical assessment.